MacroGenics
IPODeveloping innovative antibody-based cancer therapeutics
Public · United States · $75.5M raised
- Business Model
- B2B
- Website
- macrogenics.com
- Total Funding
- $75.5M
- Last Round
- $30.5M Series BSep 2001
- Rounds
- 3
- Type
- Public
About
Clinical-stage biopharmaceutical company discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer.
Summary
MacroGenics is a Biotech company based in United States. It has raised $75.5M in total across 3 rounds, most recently a $30.5M Series B round in Sep 2001. Investors include Alta Partners, TPG (Growth/Rise) and Clarus Ventures.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2013
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...